BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tell Proactive the group posted third-quarter results on Thursday that saw its revenue jump 60% year-over-year on the back of contributions from all four of its divisions including its subsidiary Clyra Medical Technologies. Clyra Medical Technologies President Steve Harrison adds that the group has successfully executed the first phase of the Clyraguard product launch, a personal disinfectant spray designed to decontaminate masks and other PPE, which is now available at www.clyramedical.com.
BioLargo reveals 60% rise in 3Q revenue amidst roll-out of PPE disinfectant spray Clyraguard
Quick facts: BioLargo, Inc.
Price: 0.1499 USD
Market Cap: $33.34 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of BioLargo, Inc. named herein, including the promotion by the Company of BioLargo, Inc. in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE